Multicenter phase 3 trial of ibrutinib-venetoclax, ibrutinib alone, or FCR for CLL

The multicenter phase 3 FLAIR trial in the UK randomized CLL patients to ibrutinib plus venetoclax, ibrutinib alone, or fludarabine-cyclophosphamide-rituximab (FCR). With a median follow-up of 62.2 months, disease progression or death occurred in 6.9% of patients in the ibrutinib-venetoclax group, as compared with 22.4% in the ibrutinib-alone group (HR 0.29; p<0.001) and 42.6% in the FCR group (HR 0.13; p<0.001), whereas undetectable MRD in bone marrow within two years was achieved by 66.2%, 0%, and 48.3%, and death occurred in 4.2%, 9.9%, and 14.8%.